SEC Comment Letter 0000000000-24-003031 to Biodexa Pharmaceuticals Plc (BDRX)
Biodexa Pharmaceuticals Plc
Date: March 20, 2024 · CIK: 0001643918 · Accession: 0000000000-24-003031
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278040
Letter
United States securities and exchange commission logo March 20, 2024 Stephen Stamp Chief Executive Officer Biodexa Pharmaceuticals Plc Caspian Point Caspian Way Cardiff, CF10 4DQ, United Kingdom Re:Biodexa Pharmaceuticals Plc Registration Statement on Form F-1 Filed March 18, 2024 File No. 333-278040 Dear Stephen Stamp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Donald J. Puglisi
Show Raw Text
United States securities and exchange commission logo
March 20, 2024
Stephen Stamp
Chief Executive Officer
Biodexa Pharmaceuticals Plc
Caspian Point
Caspian Way
Cardiff, CF10 4DQ, United Kingdom
Re:Biodexa Pharmaceuticals Plc
Registration Statement on Form F-1
Filed March 18, 2024
File No. 333-278040
Dear Stephen Stamp:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Donald J. Puglisi